David Fell, MD
Ophthalmology · Plymouth Meeting, PANPI 1962990556
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 46.4% of the total. Reporting peaked in 2023 at $3,783 and has fallen 58.4% since, to $1,574 in 2025.
Across 50 payments — averaging $133.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$3K
- Alcon$1K
- AbbVie$471
- Apellis Pharmaceuticals, Inc.$424
- Regeneron$277
- Heidelberg Engineering, Inc.$205
- plus $710 from 8 others
What the payments were for
- Consulting fees$80012%
- Travel & lodging$2,19133%
- Food & beverage$3,56154%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 22 | $3,084 |
| Alcon | 6 | $1,481 |
| AbbVie(2 entities) | 5 | $471 |
| Apellis Pharmaceuticals, Inc. | 4 | $424 |
| Regeneron | 2 | $277 |
| Heidelberg Engineering, Inc. | 1 | $205 |
| Alimera Sciences, Inc. | 2 | $163 |
| Eyepoint US, Inc. | 2 | $153 |
| Omeros Corporation | 1 | $125 |
| Astellas Pharma US Inc | 1 | $122 |
| Genentech USA, Inc. | 1 | $85 |
| Tarsus Pharmaceuticals, Inc. | 1 | $30 |
| Biotissue Holdings Inc. | 1 | $17 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS ELITE$2,033
- STELLARIS$377
- OZURDEX$331
- EYLEA HD$277
- Syfovre$277
- Spectralis$205
- Constellation$154
- Unity$131
- OMIDRIA$125
- Izervay$122
- Iluvien$122
- XIPERE$115
- YUTIQ$107
How this compares
$6,652 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 130 | $5,054 |
| Bromfenac Sodium | 17 | $4,167 |
| Difluprednate | 14 | $1,134 |
| Ofloxacin | 34 | $437 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $404 |
| Ketorolac Tromethamine | 14 | $377 |
| Latanoprost | 19 | $271 |
| Timolol Maleate | 12 | $188 |
| Brimonidine Tartrate | 25 | $155 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Plymouth Meeting
- Carl RegilloPlymouth Meeting$721K
- Michael KlufasPlymouth Meeting$393K
- Ajay KuriyanPlymouth Meeting$226K
- Allen HoPlymouth Meeting$225K
- Sunir GargPlymouth Meeting$216K
- Yoshihiro YonekawaPlymouth Meeting$95K
- Omesh GuptaPlymouth Meeting$85K
- Sonia MehtaPlymouth Meeting$49K
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.